^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microbiome modulator

    Related drugs:
    16d
    adored: Allergic Disease Onset Prevention Study (clinicaltrials.gov)
    P1/2, N=283, Completed, Siolta Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    1m
    A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC (clinicaltrials.gov)
    P2, N=87, Recruiting, LISCure Biosciences | Not yet recruiting --> Recruiting | Initiation date: Mar 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    2ms
    Medicinal Cannabis for Endometriosis: The Gut Microbiome (ACTRN12624000828527)
    P2, N=28, Not yet recruiting, Western Sydney University | N=42 --> 28
    Enrollment change
    2ms
    KAN-004 for Immune-Related Diarrhea or Colitis (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Centre hospitalier de l'Université de Montréal (CHUM)
    New P1 trial
    2ms
    Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent Cystitis (clinicaltrials.gov)
    P4, N=100, Recruiting, Mahidol University
    New P4 trial
    3ms
    Two microbiome metabolites compete for tRNA modification to impact mammalian cell proliferation and translation quality control. (PubMed, Nat Cell Biol)
    The microbiome affects eukaryotic host cells via many metabolites, including the well-studied queuine as substrate for host tRNA queuosine modification...We identify the endoplasmic reticulum-localized inositol-requiring enzyme 1 (IRE1) ribonuclease as the enzyme responsible for the selective degradation of preQ1-modified tRNAs on translating ribosomes. Our results identify two microbial metabolites competing for host tRNA modification, which elicits translation quality control and impacts cell proliferation.
    Journal
    |
    ERN1 (Endoplasmic Reticulum To Nucleus Signaling 1)
    3ms
    CP101 for the Treatment of Ulcerative Colitis (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Brigham and Women's Hospital | Trial completion date: Jun 2025 --> Dec 2025
    Trial completion date
    3ms
    VE202-002: VE202 in Patients With Mild-to-Moderate Ulcerative Colitis (clinicaltrials.gov)
    P2, N=114, Terminated, Vedanta Biosciences, Inc. | Results indicated that VE202 was not superior to placebo on the primary or any of the secondary endpoints. No new safety concerns were observed.
    Trial termination
    3ms
    High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    3ms
    PICASSO: Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (clinicaltrials.gov)
    P2, N=70, Completed, Assistance Publique - Hôpitaux de Paris | Recruiting --> Completed | Trial completion date: Jun 2024 --> Apr 2025 | Trial primary completion date: Jan 2024 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Xervyteg (MaaT013)
    3ms
    Mechanism of Bao Gan Ning Decoction in attenuating hepatic fibrosis via modulation of the gut microbiome and PPAR/CYP7A1-mediated bile acid metabolism. (PubMed, J Ethnopharmacol)
    BGN alleviates HF through gut microbiota-dependent restoration of BA homeostasis and activation of the PPARα/CYP7A1 pathway. This study provides novel mechanistic insights into BGN's anti-fibrotic activities, positioning it as a microbiota-modulating therapeutic candidate for HF management.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    3ms
    COMPOSER-1: A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, Microbiotica Ltd | Recruiting --> Active, not recruiting
    Enrollment closed